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Abstract
This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic
response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two
scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic
susceptibility score (cGSS)] were developed. Each drug in the subject's regimen was given a
binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In
contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both
GSS were independent predictors of week 16 virologic response. We also compared the GSS to a
phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS
performed, and found that both models were predictive of virologic response. Genotypic analyses
at enrollment showed that subjects who were virologic nonresponders at week 16 revealed
enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors
(NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88)
compared to subjects who were virologic responders. Regression analyses revealed that protease
mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations
at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations,
such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may
be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic
response and improve treatment outcomes.
Introduction
Antiretroviral therapy (ART) has been well documented to decrease HIV-1 RNA viral load
as well as HIV-1-associated morbidity and mortality.1-5 Unfortunately, virologic rebound
commonly occurs in treatmentnaive and treatment-experienced patients.6-8 Persistent viral
replication in the setting of drug selection can lead to the appearance of amino acid
substitutions that confer resistance to the current regimen. Thus, identification of patients
with acquired drug resistance mutations is critical to achieve virologic suppression and
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improve patient outcome. To this end, testing for resistance to antiretrovirals is standard of
care, and current guidelines recommend resistance testing for treatment failure during
chronic infection.9,10
Resistance testing is important in guiding the medical management of HIV-1-infected
individuals and has been shown to improve virologic response,11-15 but it remains unclear
which method of resistance testing is most useful. Currently, there are three methods to
evaluate HIV-1 resistance: genotype, phenotype, and virtual phenotype. Determining which
interpretation model is most sensitive and valid is a subject of ongoing intense investigation
as there are advantages and disadvantages to each. Improved strategies to interpret viral
resistance are necessary to predict the complex relationship between drug effects and
virologic and immunologic outcomes.
In the current study, we extended our analyses of the AIDS Clinical Trials Group (ACTG)
Study 359, a study of treatment-experienced patients who underwent drug resistance testing
prior to receiving a regimen based on a combination of two new protease inhibitors (PIs) (a
detailed summary is given in Materials and Methods). In doing so, we have tested two
scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic
susceptibility score (cGSS)] to explore the relationship between the genotypic resistance
pattern at the time of study entry and virologic response through week 16.
Materials and Methods
ACTG 359 study subjects
The results of the original clinical study have been published previously.16 Written informed
consent was obtained from all patients or their guardians, and the human experimentation
guidelines of the U.S. Department of Health and Human Services and the individual
institutions were followed in conducting this research. Briefly, ACTG 359 was a
randomized, partially-blinded, multicenter 2 × 3 factorial trial that was designed to test the
efficacy of two new PIs, ritonavir (RTV) and saquinavir (SQV) or nelfinavir (NFV) and
SQV, in conjunction with a new nucleoside reverse transcriptase inhibitor (NRTI) [adefovir
dipivoxil (ADV)] or NNRTI [delavirdine (DLV)], or both ADV and DLV in treatment-
experienced subjects who had experienced virologic failure while taking indinavir (IDV).
Eligible subjects had an HIV-1 RNA viral load of 2000–200,000 copies/ml (Amplicor
HIV-1 Monitor test version 1.0; Roche Diagnostic Systems). Subjects were assigned to
study therapy for a minimum of 24 weeks. Clinical assessments and routine laboratory tests
were performed at baseline and every 4 weeks through week 16, and at 8 week intervals
thereafter.
Genotypic analyses
Plasma was obtained at each visit and assayed in real time for HIV-1 RNA (Roche Amplicor
HIV-1 Monitor test) at a central laboratory at University of North Carolina or University of
Washington. HIV-1 viral RNA was extracted from EDTA-treated plasma using the QIAamp
viral RNA isolation kit (Qiagen). RT-PCR and sequencing were performed using the
TRUGENE™ HIV-1 Genotyping kit from Bayer Diagnostics, according to the
manufacturer's instructions, to identify the presence of resistance-associated mutations in the
pro gene (encoding the viral protease) and over the first 240 codons of the pol gene
(encoding the viral DNA polymerase reverse transcriptase). Sequences were analyzed using
the Bayer Diagnostics OpenGene system, version 3.1.5 software. Amino acid sequences
were deduced and mutations associated with NRTI, NNRTI, or PI resistance were reported
with respect to wild-type virus HXB2.
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We explored two scoring methods to describe the relationship between antiretroviral
resistance and therapy outcome. In each method, a resistance score was calculated using the
Stanford Inferred Drug Resistance Scores,17 version 4.2.1, to assess the impact of resistance
mutations on predicted drug susceptibility; GSS to RTV was based on version 4.2.0, the last
version that still included RTV as a PI drug. Susceptibility to each drug in the study regimen
was considered. In the first method, a discrete value of 1 or 0 was given if the Stanford score
was below 30 (susceptible) versus 30 or above (resistant). The values (0 or 1) for each of the
drugs in the subject's regimen were summed to create dGSS. Since resistance scores to ADV
are unavailable in Stanford rules and previous phenotypic analyses have shown ADV to be a
less potent drug, a resistance score for ADV was set to 0 in the dGSS calculation; RTV was
assigned a weight of 0.5 for being used as a PI booster.18
In the second method, the cGSS was generated to reflect partial susceptibility to a drug.
Intermediate susceptibility scores between 1 and 0 were calculated if the Stanford resistance
score ranged from 10 to 60 [(60 – Stanford resistance score) ÷ (60–10)]. A score of 1 was
assigned to a sequence if the Stanford resistance score was less than 10, and 0 if 60 or
greater. Similar to the dGSS scoring method, a weighted sum of the individual values for
each drug was generated for the cGSS.
Univariate and multivariate logistic-regression models were used to examine the association
between the GSS and the primary study end point (HIV-1 RNA ≤500 copies/ml at week 16).
The predictive value of the GSS was evaluated by use of univariate and multiple censored
regression models under the assumption of normal error distribution.19 Descriptive analyses
of mutation patterns were performed at baseline and in the subjects who were virologic
nonresponders at week 16 (HIV-1 RNA >500 copies/ml at week 16). Exact Chi-square test
or Fisher's exact test was used for comparison of proportions across groups and the Kruskal–
Wallis test for comparison of continuous variables across groups. Significance levels were
set at p = 0.05. To relate baseline mutational patterns to week 16 virologic response, two sets
of analyses were performed by either excluding subjects whose week 16 virologic responses
were missing, or treating missing week 16 virologic responses as nonresponders.
To dissect further the relationship between GSS, magnitude of entry HIV-1 RNA, and
virologic response, additional analyses were performed on subjects who were identified as
compliant failures (subjects with a transient decrease in viral RNA load and the maintenance
of baseline resistance mutations and/or the appearance of new resistance mutations) or
virologic responders; compliant failures had either new mutations at week 16 compared to
baseline or retained baseline PI mutations at week 16. Subjects with low baseline viral loads
(<10,000 copies/ml) were excluded. The remaining subjects were categorized into two
groups according to baseline HIV-1 viral RNA (10,000 to 50,000 copies/ml or >50,000
copies/ml). Since the nadir HIV-1 viral RNA during the first 16 weeks for many subjects
was below 500 copies/ml, the maximum viral load reduction was left censored. Censored
regression models were used by assuming a normal error distribution. No p-value was
adjusted for multiple testing.
Results
Baseline genotypic resistance analysis
Baseline sequence data were obtained from 234 of the 277 subjects enrolled in the trial
(84%), with the sequences well distributed between the arms [N = 34 to 42 among the
different arms with 34 in Arm A (SQV + RTV + DLV), 42 in Arm B (SQV + RTV + ADV),
37 in Arm C (SQV + RTV + DLV + ADV), 41 in Arm D (SQV + NFV + DLV), 41 in Arm
E (SQV + NFV + ADV), and 39 in Arm F (SQV + NFV + DLV + ADV)]. Of note, the
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treatment-experienced ACTG 359 study subjects had a median prior IDV use of 13.8
months, median CD4 cell count at entry of 228 cells/mm3, and mean HIV-1 viral RNA load
at entry of 32,297 copies/ml (4.51 log10 copies/ml). Overall, 30% (77 of 254) of subjects
had HIV-1 RNA levels of ≤500 copies/ml at week 16 (virologic responders). In addition,
sequence data were obtained for 141 of the 177 subjects (80%) who had experienced
virologic failure with plasma viral RNA levels greater than 500 copies/ml at week 16
(virologic nonresponders). The drug regimens in this trial had the potential for strong
selective pressure from the PIs and from a potent NNRTI. Thus the analysis of the impact
and evolution of resistance using this trial represents an opportunity to examine relevant
descriptive and statistical approaches that are generally applicable.
The NRTI resistance mutations and PI resistance mutations present at baseline are
summarized in Tables 1 and 2. Resistance mutations in RT to NRTIs were largely to
lamivudine (M184V) and zidovudine (M41L, K70R, L210W, T215F/Y, and K219Q).20 The
M184V mutation was present in 85% of subjects and a mutation at position 215 was present
in 59% of subjects. These mutation patterns are consistent with high levels of resistance to
lamivudine and a wide range of resistance to zidovudine seen in the phenotypic resistance
analysis of a subset of these same subjects.18 The D67N mutation occurred in 40% of the
subjects. In contrast, the 69 insertion complex, associated with multi-NRTI resistance,21
was not detected in any of the baseline sequences. Resistance mutations to NNRTIs were
absent as would be expected given the NNRTI-naive status for trial entry.
The baseline resistance mutations in protease were dominated by primary resistance
mutations M46I/L, I54V, V82A/F/T, and L90M (Table 2). Secondary or compensatory
mutations that were most notable were L10I, L24I, M36I, L63P, and A71V/T. Positions 46
and 82 both had approximately 50% mutation prevalence in baseline samples. These
observations are consistent with phenotypic studies, which reveal that a substitution at
residue 82 is most frequently associated with IDV resistance,22 and that a sensitive predictor
of IDV resistance can be obtained if substitutions at either residue 46 or 82 are considered.
Havlir et al. have previously shown that virologic failure to an IDV-containing regimen can
occur in the absence of resistance mutations, again consistent with only 50% of subjects in
this cohort having resistance mutations in the protease coding domain at entry.23
Correlation between GSS and therapeutic response
A series of logistic regression models were used to determine the relationship between
baseline GSS and week 16 virologic response. With dGSS or cGSS as the only variable for
week 16 outcome, we found that both scoring schemes strongly predicted virologic response
at week 16 (p = 0.0022 or 0.0015, respectively). Each additional unit increase in the dGSS
increased the odds of virologic response by about 2-fold, and 2.5-fold with the cGSS.
However, entry viral RNA load was a strong determinant of virologic response and an effect
modifier of drug resistance markers. Thus, when the dGSS and the baseline RNA were
assessed as independent variables, both were found to be independent predictors of virologic
response (p = 0.002 and 0.0007, respectively). Like-wise, a similar result was obtained when
the cGSS and baseline viral RNA load were assessed as independent variables, with even
smaller p values (p = 0.009 and 0.005). Therefore, both the dGSS and cGSS were significant
predictors of virologic outcome at week 16, independent of entry viral RNA loads. The
logistic regression models excluded the 18 subjects with missing week 16 HIV RNA
outcomes (missing excluded). When identical models were generated treating the missing 18
subjects' week 16 outcomes as nonresponders, similar results were obtained, although the p
values for the GSS increased 3- to 4-fold (data not shown).
There are a variety of clinically available genotypic drug-resistance interpretation systems,
and the most commonly used are the Stanford HIV RT and Protease sequence data-base,
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Geno2pheno, Rega, ANRS, and virtual phenotype.24-26 These are based on genotype–
phenotype correlations, known clinical outcomes, rule-based algorithms, and/or expert
opinion. In the current study, we found that two different GSS based on the Stanford HIV
RT and Protease sequence database, the dGSS and cGSS, were independent predictors of
virologic response. However, there are some limitations in using the GSS to predict viral
outcome. First, scores are scaled from 0 to 1 for all drugs, and do not adjust for individual or
combined drug potency. Second, since resistance scores to ADV are unavailable in Stanford
rules and ADV has been shown to be a much less potent drug in vivo, a score for ADV
susceptibility was set to zero. However, any ADV effect was likely small, as our data did not
reveal any significant difference in the appearance or disappearance of NRTI mutations in
the groups treated with or without ADV (see below). Third, since RTV was used as a PI
booster, it was assigned an intermediate weight of 0.5 for both GSS models. Fourth, neither
model can account for complex virus-host interactions or host differences in
pharmacokinetics. Fifth, minor variants, i.e., those comprising less than 30% of the viral
population, were not accounted for in the genotypic test used, and this is especially relevant
as 50% of subjects taking IDV at entry showed no resistance mutations in the protease gene.
Even with these limitations the GSS models were significantly correlated with outcome,
confirming previous studies of the utility of genotypic information in assessing the
likelihood of therapeutic response.11,12,27-29
Comparison of the predictive value of GSS versus PSS
Previously, we described a retrospective analysis of the utility of phenotypic
characterization of drug resistance at entry as a predictor of therapy outcome;18 a phenotypic
susceptibility score (PSS) was determined on a total of 142 subjects within the ACTG 359.
The PSS was found to be a significant predictor of virologic response at week 16. There
were 125 subjects with both baseline genotypic and phenotypic analyses, and week 16
HIV-1 RNA results available. The Spearman correlation between the value of the cPSS and
the value of the cGSS was 0.79 (p = 0.0001). Using logistic regression analysis and
correcting for baseline viral RNA load, we found that both the cPSS and cGSS were
significant predictors of virologic response in this subset of subjects, with the cGSS having a
moderately smaller p-value in this analysis (0.009 vs. 0.025) (Table 3).
The methodology of genotypic or phenotypic resistance testing has been a subject of
previous study.18,25,30-38 Our analysis adds to several trials that have attempted to compare
directly these two different methods. For the majority of these studies, the clinical outcomes
have been similar regardless of the methodology: phenotype vs. virtual phenotype39,40 and
genotype vs. virtual phenotype;33,41 however, in a subset of HIV-1-infected subjects with PI
experience, a greater proportion of subjects achieved virologic suppression using genotypic
testing vs. phenotypic testing42 to guide antiviral selection. Although the optimum
interpretation system has yet to be determined, our data suggest that the genotypic
susceptibility scores perform similarly to the phenotypic susceptibility score in being
correlated with virologic outcome.
Resistance mutations present at entry that are overrepresented, lost, or newly evolved in
the subjects who experienced virologic failure at week 16
Among the 216 subjects with available baseline genotypic data and week 16 HIV-1 RNA
data, 67 of 216 (31%) had a favorable virologic response (week 16 HIV RNA ≤500 copies/
ml). To determine the relationship between resistance mutations present at entry and
virologic response, we compared the frequencies of wild-type or mutant codons at week 16
for those subjects with and without a virologic response (Tables 1 and 2). For all
comparisons, a two-sided Fisher's exact test was used, and missing data were excluded.
Consistent with the overall week 16 response rate of 30% in the trial, the baseline wild-type
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sequences partitioned at a 2:1 ratio between the groups that experienced virologic failure vs.
response (except as outlined below). Of note, there were no NNRTI resistance mutations
present at entry to include in the analysis, and all subjects discontinued NRTI therapy with
the exception of subjects who received the minimally potent ADV.
NRTI resistance mutations
At baseline, there were several positions in the RT coding domain that were overrepresented
in the subjects who were virologic nonresponders at week 16 (Tables 1 and 4). Subjects with
mutations at position 67 (D to E/G/N), 69 (T to A/D/N/S), 70 (K to R/G/E), and 118 (V to I)
were significantly enriched in those who were virologic nonresponders (p = 0.005, 0.005,
0.02, and 0.013, respectively). In addition, although at positions 215 and 219, there were
similar rates of wild-type vs. mutant codons present in the virologic responders and
nonresponders, there was a statistically significant overrepresentation of the thymidine
analog resistance mutations T215F (16% vs. 1.5%) and K219Q (17.5% vs. 4.5%) in the
virologic nonresponders vs. the virologic responders (p = 0.002 and 0.015, respectively).
However, the more common T215Y mutation partitioned equally among the responders and
nonresponders. The enrichment of T215F and K219Q in the subjects who were virologic
nonresponders correlates with the differential evolution of the TAM-1 cluster (M41L,
L210W, and T215Y) vs. TAM-2 cluster (K70R, T215F, and K219Q),43-45 and is possibly
due to steric constraints on the ATP site as assessed by molecular modeling approaches and
known ATP-protein interactions or fitness differences (see below).46
In comparing the week 16 sequences of the virologic non-responders to their entry
sequences there were three codons associated with NRTI resistance that showed changes not
involving a reversion to wild type. The most frequent position with new mutations was at
position 215, where changes were detected in 18 sequences (13% of subjects). However, the
substitutions were not the common TAMs (215 T to F or Y). Instead, the 215 position was
enriched for the phenotypic reversion substitutions S/Z/I/D/C/V. In addition, two new
polymorphisms were detected in the TAM position 219. At position 184, there were two
subjects who gained the M184I substitution. Like M184V, this substitution is associated
with high level resistance to 3TC and FTC. The only other new NRTI resistance mutation
was a L74V substitution (associated with resistance to DDI and ABC) in one subject in the
DLV arm. The appearance of these latter substitutions (M184I and L74V) likely represents
the fortuitous outgrowth of viral subpopulations that were initially present at baseline and
evolved linked resistance mutations for which there was selective pressure. Although ADV
is known to have minimal NRTI activity, as expected we did not detect any significant
difference in the gain or loss of any TAM at week 16 when comparing groups with or
without ADV; p-values at baseline and 16 weeks for these NRTI resistance mutations in the
DLV or ADV arms are all >0.16.
NNRTI resistance mutations
Multiple NNRTI mutations have been associated with DLV resistance: K103N, V106M,
Y181C, Y188L, and P236L.20 Although none of these was present at entry, a total of 53
NNRTI resistance mutations were detected in the 141 virologic nonresponders in the DLV-
containing arms (Tables 1 and 4). As expected, none of the subjects treated with ADV, but
not DLV, developed any NNRTI-associated mutations. The most frequently observed
mutation was K103N, which was detected in 34 subjects. Y181C arose in 17 subjects, and
P236L was seen in two subjects.
We also wanted to determine whether potent NNRTI drug selection had an effect on
reversion of TAMs or loss of M184V in the absence of ongoing NRTI drug selection. To
address this question, we analyzed resistance mutations at baseline and week 16 in the
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subgroup of patients that received only DLV, but not ADV (in addition to the PIs) and fixed
an NNRTI-resistance mutation (19 subjects). In the subjects that developed either K103N or
Y181C in the DLV arm, 12 of 17 subjects (71%) maintained all of their baseline TAM
mutations. In addition, the rate of M184V retention in the DLV arm was relatively similar
(65% retained M184V). These data indicate that in the absence of potent NRTI drug
selection, there is no strong tendency for unselected NRTI resistance mutations to revert
back to or be replaced by the wild-type pol sequence while fixing a strongly selected NNRTI
mutation. However, when NRTI resistance mutations were lost, this was more likely to
occur in arms that contained DLV compared to the arms without DLV; 24% of the week 16
sequences in the DLV-containing arms lost one or more TAMs compared to only 8% in the
DLV-negative arms (p = 0.01). M41L was the most common TAM that was lost (either
alone or in combination, at a frequency of 20%). The persistence of NNRTI mutations has
been well documented despite the absence of drug selection for up to 12 months, indicating
minimal effect of NNRTI mutations on viral fitness.47 Thus, while NNRTI resistance
mutations were easily added to the background NRTI mutations in many cases, a presumed
cumulative effect of fitness loss was also suggested with the more pronounced loss of NRTI
mutations in the DLV arms. A potential factor leading to the relative enrichment of various
NRTI mutations in the subjects who were virologic nonresponders is NNRTI
hypersusceptibility.48,49 The presence of mutations at three RT codons (215, 208, and 118)
is independently associated with hypersusceptibility to NNRTIs.50,51 Of note, T215Y was
highly predictive of NNRTI hypersusceptibility, whereas T215F was not predictive. Our
observation of the overrepresentation of T215F but not T215Y in the subjects who were
virologic nonresponders is consistent with the T215Y mutation conferring NNRTI
hypersusceptibility.
PI resistance mutations
At baseline, there were several mutations within pro that were overrepresented in the
virologic nonresponders (Tables 2 and 4). Mutations at position 10 (L to F/I/R/V), 24 (L to
I), 71 (A to T/V/I), 73 (G to C/S/T), and 88 (N to D/S/T) were enriched in the nonresponder
samples relative to the wild type (all p values < 0.05). There were relatively few examples of
I47V, but these were overrepresented in the virologic responders (p = 0.038) indicating a
protective effect. The M46I mutation approached statistical significance (p = 0.057) for
being overrepresented in the nonresponders, while the M46L mutation had the same
partitioning as the wild type. As expected, the position most frequently substituted among
this group of IDV-experienced subjects was position 82 (present in approximately 50% of
subjects); however, mutations at this position were partitioned equally among the virologic
responders and nonresponders. The I84V and L90M mutations would be expected to
contribute to resistance to regimens containing SQV and NFV, and both of these primary
resistance mutations showed a trend in the nonresponders.
The differential partitioning of baseline PI resistance-associated mutations in the viral strains
of nonresponders largely paralleled increases seen in the frequency of protease mutations in
the week 16 sequence of these subjects, especially for primary resistance mutations (Table
2). The following mutations were significantly increased at week 16 compared to their
paired entry sample: L10I, M36I, F53L, I54V, A71V, G73S, I84V, and L90M (all p values
<0.02). In general, there was a trend for higher incidence of PI resistance mutations at week
16, with two exceptions. There was a significant decrease in I93L from 52% to 43% (p <
0.004) from 73 of 141 subjects at baseline to 61 of 141 subjects at week 16. In addition,
there was a trend for the loss of V82A (p = 0.08) even though I54V, which is frequently
seen as a compensatory mutation to V82A,52,53 increased. There was no statistically
significant increase in L24I, M46I, L63P, or N88S, suggesting that although they could
contribute to resistance as evidenced by their enrichment in the nonresponder subset, they
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were not selected for resistance pathways when more mutations appeared. These data
suggest that the V82A pathway commonly seen with IDV (and RTV) did not participate in
the evolution of resistance to the SQV and NFV-based PIs. Consistent with these data,
mutations at position 82 were associated with greater reductions in viral RNA load, while
mutations at positions 24 and 90 were associated with smaller reductions in viral RNA load
(see below).
Discussion
Both GSS and viral RNA load predict the magnitude of the viral RNA load decrease
In the previous models, we used the primary endpoint of the ACTG 359 study (viral load
≤500 copies/ml at week 16) to define virologic response. We also generated a series of
logistic regression analyses using as the endpoint a 1.5 log10 decrease in viral RNA load or
viral load ≤500 copies/ml at any point during the first 16 weeks since the viral load nadir
could occur prior to week 16 and then rebound. In these analyses, both the dGSS and the
cGSS continued to be predictors of virologic outcome (data not shown). However, the
baseline viral load remained a significant predictor of the magnitude of the viral RNA
decrease. This observation suggests that the magnitude of the drop in viral RNA load is in
part dependent on the baseline level of viral RNA, with the drop being proportionately
smaller with higher viral RNA loads. To dissect the relationship between GSS, entry viral
load, and virologic outcome, we used censored regression models of subjects with entry
HIV-1 RNA between 10,000 and 50,000 copies/ml, and those with HIV-1 RNA >50,000
copies/ml. As expected, the cGSS was a strong predictor of the magnitude of the viral RNA
drop. However, the magnitude of the drop as predicted by the cGSS was reduced by 0.57
log10 among the subjects with higher entry viral RNA levels, suggesting less drug efficacy
per unit cGSS among subjects with high viral RNA loads. One limitation in this analysis is
that subjects with baseline viral loads greater than the median had dGSS and cGSS
significantly lower than those subjects with viral loads less than the median (p = 0.004 and
0.002, respectively); thus inaccuracies in assigning the GSS values would be biased between
the two groups.
Scaling the viral RNA load decrease to the GSS does not predict the virologic response
We created a dataset with a subset of the virologic nonresponders at week 16 and for whom
there was clear evidence of new drug exposure and some measure of treatment compliance
(a transient decrease in viral RNA load and the maintenance of baseline resistance mutations
and/or the appearance of new resistance mutations). The goal in making this data set was to
be able to evaluate the magnitude of change in viral RNA load in subjects who were largely
adherent. In comparing the arms that either did or did not include DLV there was a 0.4 log
difference in the extent of viral RNA load drop (1.08 log10 with DLV vs. 0.68 log10 without
DLV). We next used regression analysis after adjusting for the effect of DLV to determine
which PI resistance mutations most impacted virologic response as measured by maximum
decline in HIV-1 RNA. Three positions were found that impacted outcome using a
backward or forward selection model. Position 82 was associated with enhanced virologic
response by 0.47 log10 (p = 0.03). In contrast, mutations at positions 24 and 90 were
associated with an increase in HIV-1 RNA by 0.71 and 0.75 log10 (p = 0.005 and 0.0004,
respectively). Finally, we used the model developed based on data from the virologic
nonresponders to examine the magnitude of the viral RNA drop in the virologic responders.
However, the parameters derived from the subjects who were nonresponders did not predict
the magnitude of the drop in the virologic response (data not shown). It is not clear why we
were unable to link the empirically derived data for drug potency, as defined by viral RNA
load drop in the compliant nonresponders, to model viral RNA load drop in the virologic
response. The strong linkage between entry viral load and therapeutic response suggests this
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relationship should exist. The scaling of the resistance mutations to account for differences
in the level of viral RNA drop may be too inaccurate to have predictive power in the absence
of resistance mutations. Also, we did not measure the additional host cellular, humoral, or
innate immunologic responses, variation in pharmacogenomics and drug metabolism, or
genetic regulation of viral replication among individuals, each of which may contribute to
the effectiveness of antiretroviral therapy and viral suppression.
In summary, we have shown the utility of a GSS as a significant predictor of therapy
outcome and compared this approach to a PSS. We were able to examine the role of
resistance mutations in the context of mutations at entry and their over- or
underrepresentation in subjects who were virologic nonresponders, to compare these
patterns to the appearance of new mutations, to define mutations that enhanced or reduced
the virologic response, and to show that potently selected new mutations can be added onto
the backbone of previous mutations even in the absence of the previous selective drug
pressure (e.g., subjects that developed K103N or Y181C in the DLV arm who maintained
baseline TAMs, n = 12 of 17 subjects). Finally, we explored the relationship between the
GSS and the magnitude of viral RNA drop in subjects with a successful virologic response
or lack thereof, and found discrepancies in comparing these two groups. Collectively, these
studies represent a comprehensive exploration of the role of baseline resistance mutations in
this cohort during salvage therapy.
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Table 1






















41M (wt) 128 79 36 81
41L 106 70 31 60
67D (wt) 132 73 47 76
67E/G/N 2, 6, 94 1, 5, 70 1, 1, 18 1, 2, 62
69T (wt) 195 118 63 112
69A/D/N/S/Z 2, 20, 17, 1, 2 2, 16, 13, 1, 1 0, 2, 2, 0, 0 1, 15, 12, 2, 1
70K (wt) 171 101 56 99
70R/G/E 62, 2, 1 47, 2, 1 11, 0, 0 41, 2, 1
103K (wt) 234 149 67 107
103N 0 0 0 34
118V (wt) 199 120 63 113
118I 35 29 4 28
181Y (wt) 234 149 67 124
181C 0 0 0 17
184M (wt) 35 21 8 68
184I/V 0, 199 0, 128 0, 59 2, 73
210L (wt) 162 107 47 103
210W/Z 63, 2 41, 1 19, 1 37, 1
215T (wt) 96 58 29 62
215C/D/F/I/V/S/Y/Z 0, 0, 26, 2, 1, 5, 111, 4 0, 0, 24, 1, 1, 3, 68, 2 0, 1, 1, 0, 2, 35, 1 1, 1, 21, 5, 2, 14, 60, 7
219K (wt) 185 112 57 103
219E/N/Q/R/Z 12, 4, 30, 2, 2 6, 3, 26, 1, 2 6, 1, 3, 0, 0 6, 3, 25, 1, 4
236P (wt) 234 149 67 139
236L 0 0 0 2
a
Z represents any other polymorphism different from wild-type.
b
Positions with low frequencies of substitutions that were not significantly different or associated with a virologic response include codons 44, 62,
65, 74, 75, 77, 100, 115, 116, and 151.
c
Numbers in bold font (p value <0.05).
d
Virologic nonresponders = subjects with HIV-1 viral RNA load >500 copies/ml.
e
Virologic responders = subjects with HIV-1 viral RNA load ≤500 copies/ml.
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Table 2


















10L (wt) 127 71 46 60
10F/I/R/V/Z 14, 87, 6, 9, 2 10, 62, 4, 8, 1 3, 18, 1, 0, 0 10, 72, 1, 6, 0
24L (wt) 210 130 65 118
24I/F/Z 24, 0, 0 19, 0, 0 2, 0, 0 22, 1, 1
36M (wt) 194 122 56 105
36I/L 38, 3 25, 2 10, 1 34, 2
46M (wt) 117 67 39 74
46I/L/V 84, 49, 0 62, 28, 0 19, 15, 0 49, 25, 1
47I (wt) 221 145 60 140
47V 13 4 7 1
48G (wt) 234 149 67 128
48V/Z 0, 0 0, 0 0, 0 11, 2
53F (wt) 229 146 67 118
53L/Y/Z 4, 0, 1 2, 0, 1 2, 0, 0 21, 1, 1
54I (wt) 190 118 57 92
54T/V/A/L 1, 43, 2, 0 0, 30, 1, 0 1, 10, 1, 0 0, 47, 0, 2
63L (wt) 28 15 11 13
63P/Z 181, 33 122, 16 46, 12 117, 16
71A (wt) 139 83 47 66
71T/V/I 32, 64, 5 21, 46, 4 8, 12, 1 16, 59, 6
73G (wt) 202 122 65 103
73C/S/T/Z 4, 23, 5, 1 4, 19, 4, 1 0, 1, 1, 0 5, 30, 9, 4
82V (wt) 117 77 33 82
82A/F/I/S/T 96, 11, 3, 2, 17 61, 4, 1, 2, 11 26, 6, 0, 0, 5 49, 2, 2, 1, 7
84I (wt) 222 139 65 101
84V/A/Z 12, 0, 0 10, 0, 0 2, 0, 0 40, 3, 2
88N (wt) 219 135 66 128
88D/S/T/Z 9, 5, 1, 1 8, 5, 1, 1 1, 0, 0, 0 7, 5, 1
90L (wt) 191 115 59 77
90M 43 34 8 65
93I (wt) 114 72 33 80
93L/Z 120, 1 77, 0 34, 1 61, 0
a
Z represents any other polymorphism different from wild-type.
b
Positions with low frequencies of substitutions that were not significantly different or associated with a virologic response include codons 20, 30,
32, 33, and 50.
c
Numbers in bold font (p value <0.05).
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d
Virologic nonresponders = subjects with HIV-1 viral RNA load >500 copies/ml.
e
Virologic responders = subjects with HIV-1 viral RNA load ≥500 copies/ml.
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Table 3
Logistic Regression Relating Baseline GSS or PSS to Week 16 RNA Responses
Model Variables in model OR (95% CI) P-values
1 cPSS 2.34 (1.27, 4.30) 0.006
2 cGSS 2.50 (1.42, 4.39) 0.0015
3 cPSS 2.04 (1.10, 3.81) 0.025
log10 baseline RNA 0.33 (0.19, 0.69) 0.003
4 cGSS 2.22 (1.22, 4.03) 0.009
log10 baseline RNA 0.36 (0.17, 0.73) 0.005
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Table 4
Partitioning of Mutant and Wild-Type Positions
Baseline mutations
enriched at week 16
in virologic
nonresponders
Mutation evolution at week 16
in virologic nonresponders
NRTI NRTI gain NRTI loss
 67, 69, 70, 118,  T215S/Z/I/D/C/V  M41L
 T215F  K219Z  M184V






PI PI gain PI loss
 10, 24, 71, 73, 88  Secondary = L10I, M36I, F53L, A71V  I93L, V82A
 M46I, I84V, L90M  Primary = G48V, I54V, G73S, I84V, L90M
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